Curaderm BEC5

Non-surgical alternatives for skin cancer

An alternate that's natural, Curaderm is a naturally derived product developed for non melanoma skin cancer.

Curaderm BEC5 is not recommended for Melanoma & Squamous Cell Carcinoma that has already metasticised.

Curaderm is a topical cream that is applied over the skin lesions.

How do I apply it?

You apply the Curaderm BEC5 to dry clean skin.

How much Curaderm do I apply?

You apply a thin layer (about 2 millimetres thick) of Curaderm BEC5 to the skin. You do not need to rub the product in. When you apply a pad to the Curaderm BEC5, it will spread out, this will cover the area. Please cover the lesion plus a small amount of the skin around it with Curaderm BEC5. Do not spread it to far, as the pad will spread it for you. Once the treatment starts your lesion may appear larger and you may need to apply more Curaderm BEC5 to the lesion. But once it starts to recede, please apply less. One bottle of Curaderm can cover 5 - 6 small Keratosis, so please keep it in the fridge as it can last 5 years.

Do I keep the lesion covered up during treatment?

Please keep the lesion covered during treatment with a micropore tape or a medical pad for larger lesions. These products are obtainable from your local pharmacy. This helps keep the Curaderm BEC5 on the lesion and also helps protect it during treatment. (3M Micropore Non-Sterile Tan Skin-Friendly Paper Medical Tape)

How long do I treat the lesion for?

Please keep applying the Curaderm BEC5 until the lesion is completely gone.

NOTE:
When using Curaderm, people often think they have an infection but in majority of cases this is just the dead cells. If you experience discharge or fluid during treatment with Curaderm it is mostly likely dead cells that are being mopped up by phagocytes (white blood cells).

If you would like to use a infection prevention product there are some suggestions:

• Dettol
• Peroxide
• Mentholated Spirits
• Hibiclens

Please do not use Neosporin!

After treating the lesion with these products, please rinse the lesion with water and than dry completely (without rubbing the lesion) before applying the Curaderm cream.


Watch:

• How to use Curaderm | Curaderm BEC5 Skin Cancer Treatment

Ingredients:

• Solasodine Glycosides (BEC) (active anti-cancer ingredient)
• Salicylic Acid
• Urea

Curaderm contain no fragrances or any other ingredients.

What is Solasodine Glycosides (BEC)?

Solasodine Glycoalkaloids are extracted from Eggplants and what we call BEC. BEC is the anti-cancer agents found in Curaderm.

Curaderm was tested over a 25 year period. This clinical testing & research involved basic research, pre-clinical and clinical research. Dr Bill Cham is the inventor of BEC and the inventor of Curaderm BEC5.

Please note that the Salicylic Acid and Urea may irritate the skin of some people and may create some stinging or skin sensitivity.

1985

Thorne, H.V., Clarke, G.F. and Skuce, R. (1985) The inactivation of herpes simplex virus by some Solanaceae glycoalkaloids. Antivirus Research, 5, 335-343.

doi:10.1016/0166-3542(85)90003-8


1987

Cham, B.E. and Wilson, L. (1987) HPLC of glycoalkaloids from Solanum sodomaeum L. Planta Medica, 53, 59-61.

doi:10.1055/s-2006-962621


Cham, B.E., Gilliver, M. and Wilson, L. (1987) Antitumour effects of glycoalkaloids isolated from Solanum sodomaeum L. Planta Medica, 53, 34-36.

doi:10.1055/s-2006-962612


Cham, B.E. and Meares, M.M. (1987) Glycoalkaloids from Solanum sodomaeum L. are effective in the treatment of skin cancers in man. Cancer Letters, 36, 111-118.

doi:10.1016/0304-3835(87)90081-4

1990

Daunter, B. and Cham, B.E. (1990) Solasodine glycosides. In vitro preferential cytotoxicity for human cancer cells. Cancer Letters, 55, 209-220.

doi:10.1016/0304-3835(90)90121-D


Cham, B.E. and Daunter, B. (1990) Solasodine glycosides. Selective cytotoxicity for cancer cells and inhibition of cytotoxicity by rhamnose in mice with sarcoma 180. Cancer Letters, 55, 221-225.

doi:10.1016/0304-3835(90)90122-E


1991

Cham, B.E., Daunter, B. and Evans, R. (1991) Topical treatment of malignant and premalignant skin cancers by very low concentrations of a standard mixture of solasodine glycosides. Cancer Letters, 59, 183-192.

doi:10.1016/0304-3835(91)90140-D


1993

Cham, B.E. (1993) Efficacy and mode of action of solasodine glycosides (BEC) on cancer cells. Proceedings of 4th Oceania Symposium, Bioconcepts Publishing, 41- 51.


1994

Cham, B.E. (1994) Solasodine glycosides as anti-cancer agents: Pre-clinical and clinical studies. Asia Pacific Journal of Pharmacology, 9, 113-118.


1996

Nakamura, T., Komori, C., Lee, Y., Hashinoto, F., Yahara, S., Nohara T. and Ejina, A. (1996) Cytotoxic activities of Solanum steroidal glycosides. Biological Biopharmaceutical Bulletin, 19, 564-566.

doi:10.1248/bpb.19.564


Hsu, S.H., Tsai, T.R., Lin, C.N., Yen, M.H. and Kuo, K.W. (1996) Solamargine purified from Solanum incanum Chinese herb triggers gene expression of human TNFR1 which may lead to apoptosis. Biochemical and Biophysical Research Communication, 229, 1-5.

doi:10.1006/bbrc.1996.1748


Chataing, B., Concepcion, J.L., Buitrago de Cristancho, N. and Usubillaga, A. (1996) Clinical study of the effectiveness of extracts alkaloids obtained of the fruits of Solanum americanum miller on herpes simplex, herpes two zoster and genital herpes. Rev. Fac Pharmacy, Univ. Los Andes, 32, 18-25.


1998

Chang, L.C., Tsai, T.R., Wang, J.J., Lin, C.N. and Kuo, K.W. (1998) The rhamnose moiety of solamargine plays a crucial role in triggering cell death by apoptosis. Biochemical and Biophysical Research Communication, 242, 21-25.

doi:10.1006/bbrc.1997.7903


1999

Kuo, K.W. and Lin, C.N. (1999) Pharmacological composition for treating cancer cells. US Patent No. 6214803.


2000

Kuo, K.W., Hsu, S.H., Li, Y.P., Lin, W.L., Liu, L.F., Chang, L.C., Lin, C.C., Lin, C.N. and Sheu, H.M. (2000) Anticancer activity evaluation of the Solanum glycoalkaloid solamargine. Triggering apoptosis in human hepatoma cells. Biochemical Pharmacology, 60, 1865-1873.

doi:10.1016/S0006-2952(00)00506-2


2002

Esteves-Souza, A., Silva T.M. and Alves, C.C.F. (2002) Cytotoxic activities against Ehrlich carcinoma and human K562 leukemia of alkaloids and flavonoid from two Solanum species. Journal of Brazil Chemical Society, 13, 838- 842.

doi:10.1590/S0103-50532002000600017


Solbec Pty Ltd. http://www.solbec.com.au


2004

Lee, K.R., Kozukue, N.J., Han, S.J., Park, H., Chang, E.Y., Back, E.J., Chang J.S. and Friedman, M. (2004) Glycoalkaloids and metabolites inhibit the growth of human colon (HT29) and liver (HepG2) cancer cells. Journal of Agricultural Food Chemistry, 52, 2832-2839.

doi:10.1021/jf030526d


Liu, L.F., Liang, C.H., Shiu, L.Y., Lin, W.L., Lin, C.C. and Kuo, K.W. (2004) Action of solamargine on human lung cancer cells-enhancement of the susceptibility of cancer cells to TNFs. FEBS Letters, 577, 67-74.

doi:10.1016/j.febslet.2004.09.064


2005

Lipscombe, R.J., Carter, S.J. and Ruane, M. (2005) Rhamnose binding protein. US Patent No. 6930171.


Millward, M., Powell, A., Tyson, S., Daly, P., Ferguson, R. and Carter, S. (2005) Phase I trial of coramsine (SBP002) in patients with advanced solid tumours. Journal of Clinical Oncology, 23, 3105.


2006

He, D.J. (2006) Structure and anticancer activity of glycoalkaloids. Masters Thesis.


Ono, M., Nishimura, K.K., Suzuki, T., Fukushima, K., Igoshi, H., Yoshimitsu, H., Ikeda, T. and Nohara, T. (2006) Steroidal glycosides from the underground parts of Solanum sodomaeum. Chemical Pharmacy Bulletin, 54, 230-233.

doi:10.1248/cpb.54.230


Millward, M., Powell, A., Daly, P., Tyson, R., Ferguson, R. and Carter, S. (2006) Results of phase I clinical trials of coramsine in patients with advanced solid tumours. Journal of Clinical Oncology, 24, 2070.


2007

Shiu, L.Y., Chang, L.C., Liang, C.H., Huang, Y.S., Sheu, H.M. and Kuo, K. W. (2007) Solamargine induces apoptosis and sensitizes breast cancer cells to cisplatin. Food Chemical Toxicology, 45, 2155-2164.

doi:10.1016/j.fct.2007.05.009


Liang, C.H., Shiu, L.Y., Chang, L.C., Sheu, H.M., Kuo, K.W. (2007) Solamargine upregulation of Fas, downregulation of HER2, and enhancement of cytotoxicity using epirubicin in NSCLC cells. Molecular Nutrition Research, 51, 999-1005.

doi:10.1002/mnfr.200700044


Cham, B.E. (2007) Review article. Solasodine rhamnosyl glycosides specificallybind cancer cell receptors and induce apoptosis and necrosis. Treatment for skin cancer and hope for internal cancers. Research Journal of Biological Sciences, 2,503-514.

doi=rjbsci.2007.503.514


Cham, B.E. (2007) Solasodine rhamnosyl glycosides in a cream formulation is effective for treating large and troublesome skin cancers. Research Journal of Biological Sciences, 2, 749-761.

doi=rjbsci.2007.749.761


2008

Cham, B.E. (2008) Cancer intralesion chemotherapy with solasodine rhamnosyl glycosides. Research Journal of Biological Science, 3(9), 1008-1017.

doi=rjbsci.2008.1008.1017


Punjabi, S., Cook, L.J., Kersey, P., Marks R. and Cerio, R. (2008) Solasodine glycoalkaloids: A novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo-controlled, parallel group, multicentre study. International Journal of Dermatology, 47, 78-82.

doi:10.1111/j.1365-4632.2007.03363.x


2009

Shiu, L.Y., Liang, C.H., Chang, L.C., Sheu, H.M., Tsai, E.M. and Kuo, K.W. (2009) Solamargine induces apoptosis and enhances susceptibility to trastazumab and epirubicin in breast cancer cells with low or high expression levels of HER2/neu. Bioscience Reports, 29, 35-45.

doi:10.1042/BSR20080028


2010

Sun, L., Zhao, Y., Li, X., Yuan, H., Cheng, A. and Lou, H. (2010) A lysosomal-mitochondrial death pathway is induced by solamargine in human K562 leukemia cells. Toxicology in Vitro, 24, 1504-1511.

doi:10.1016/j.tiv.2010.07.013


Sun, L., Zhao, Y., Yuan, H., Li, X., Cheng A. and Lou, H. (2010) Solamargine, a steroidal alkaloid glycoside, induces oncosis in human K562 leukemia and squamous cell carcinoma KB cells. Cancer Chemotherapy Pharmacology, 65, 1125-1130.

doi: 10.1007/s00280-010-1387-9


2011

Li, X., Zhao, Y., Wu, W.K.K., Liu, S., Cui, M. and Lou, H. (2011) Solamargine induces apoptosis associated with p53 transcription-dependent and transcription-independent pathways in human osteosarcoma U20S cells. Life Science, 88, 314-321.

doi:10.1016/j.lfs.2010.12.006


Wang, Y., Gao, J., Gu, G., Li, G., Cui, C., Sun, B. and Lou, H. (2011) In situ RBLreceptor visualization and its mediated anticancer activity for solasodinerhamnosides. Chemistry Biochemistry, 12, 2418-2420.

doi:10.1002/cbic.201100551


Li, X., Zhao, Y., Ji, M., Liu, S.S., Cui, M. and Lou, H.X. (2011) Induction of actin disruption and downregulation of HER2, and enhancement of cytotoxicity using epirubicin in NSCLC cells. Molecular Nutrition Research, 51(8), 999-1005.

doi: 10.1002/mnfr.200700044


Cham, B.E. (2011) Topical solasodine rhamnosyl glycosides derived from the eggplant treats large skin cancers: Two case reports. International Journal of Clinical Medicine, 2, 473-477.

doi:10.4236/ijcm.2011.24080


Tavares, D.C., Munari, C.C., Araujo, M.G., Beltrame, M.C., Furtado, M.H., Goncalves, C.C., Tiossi, R.F., Bastos, J.K., Cunha, W.R. and Veneziani, R.C. (2011) Antimutagenic potential of Solanum lycocarpum against induction of chromosomal aberrations in V79 and micronuclei in mice by doxorubicin. Planta Medica, 77, 1489- 1494.

doi:10.1055/s-0030-1270886


Tang, Z., Zhang, Y., Li, N., Xu, L., Zhao, B., Xiao, W., Wang, Z. and Bi, Y. (2011) Extraction, purification technology and antineoplastic effects of solamargine. Zhongguo Zhong Yao Za Zhi, Journal of Chinese Material Medicine, 36(16), 2192-2195.


Wu, C.H., Liang, C.H., Shiu, L.Y., Chang, L.C., Lin, T.S., Lan, C.E.R., Tsai, J.C., Wong, T.W., Wei, K.J., Lin, T.K., Chang, N.S. and Sheu, H.M. (2011) Solanum incanum extract (SR-T100) induces human cutaneous squamous cell carcinoma apoptosis through modulating tumor necrosis factor receptor signaling pathway. Journal of Dermatological Science, 63, 83-92.

doi: 10.1016/j.jdermsci.2011.04.003


Chase, T.R. (2011) Curaderm BEC5 for skin cancers, is it? An overview. Journal of Cancer Therapy, 2, 728-745.

doi:10.4236/jct.2011.25099


Goldberg, L.H., Landau, J.M., Moody, M.N. and Vergilis Kalner, I.J. (2011) Treatment of Bowen?s disease on the penis with low concentration of a standard mixture of solasodine glycosides and liquid nitrogen. Dermatologic Surgery, 37, 858-861.

doi:10.1111/j.1524-4725.2011.02014.x


2012

Cham, B.E. and Chase, T.R. (2012) Solasodine rhamnosyl glycosides cause apoptosis in cancer cells. Do they also prime the immune system resulting in long-term protection against cancer? Planta Medica, 78, 349-353.

doi:10.1055/s-0031-1298149


Ding, X., Zhu, F.S., Li, M. and Gao, S.G. (2012) Induction of apoptosis in human hepatoma SMMC-7721 cells by solamargine from Solanum nigrum L. Journal of Ethnopharmacology, 39, 599-604.

doi:10.1016/j.jep.2011.11.058


Cham, B.E. (2012) Intralesion and Curaderm BEC5 topical combination therapies of solasodine rhamnosyl glycosides derived from the eggplant or devil?s apple result in a rapid removal of large skin cancers. Methods of treatment compared. International Journal of Clinical Medicine, 3, 115-124.

doi: 10.4236/ijcm.2012.32024


2013

Cham, B.E. (2013) Inspired by nature, proven by science. The new generation cancer treatment that causes cancer cells to commit suicide. Published.

www.curadermbec5.com


Cham, B.E. (2013) Solasodine glycosides: A topical therapy for actinic keratosis.A single-blind, randomized, placebo-controlled, parallel group study with CuradermBEC5

doi: 10.4236/jct.2013.42076


Cham, B.E. (2013) Topical CuradermBEC5 Skin Cancer: A Review of Clinical Outcomes. International Journal of Clinical Medicine, 4(5), 233-238.

doi: 10.4236/ijcm.2013.45041


Cham, B.E. (2013) Drug Therapy: Solamargine and other solasodine rhamnosyl glycosides as anticancer agents. Modern Chemotherapy, 2(2), 33-49.

doi: 10.4236/mc.2013.22005


2014

Cham, B.E. (2014) A Review of Solasodine Rhamnosides Therapy for Cancers on the Penis. British Journal of Medicine & Medical Research, 4(2), 621-631.

doi: 10.9734/BJMMR/2014/4677